Intercept Drug’s Market Standing In PBC Undermined By Safety Woes
Ocaliva Now Contraindicated In Advanced Cirrhosis
A second FDA safety labeling update for Intercept’s Ocaliva might open a market opportunity in second-line PBC for Phase III candidates at CymaBay and Genfit.
